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psychoactive substance: 1-phenyl-2-(1-pyrrolidinyl)-
1-pentanone (α-PVP)
In accordance with Article 5 of Council Decision 2005/387/JHA 
on the information exchange, risk assessment and control of 
new psychoactive substances
About this series
EMCDDA–Europol Joint Report publications examine the detailed information 
provided by the EU Member States on individual new psychoactive substances. 
Information is collected from the Reitox network, the Europol national units and the 
national competent authorities of the European Medicines Agency.
Each Joint Report serves as the basis upon which the decision to conduct a risk 
assessment of the new psychoactive substance is taken. It is part of the three-step 
procedure involving information exchange, risk assessment and decision-making in the 
framework of Council Decision 2005/387/JHA.
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I 1. Introduction
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter 
the ‘Council Decision’) stipulates that ‘Where Europol and the 
EMCDDA, or the Council, acting by a majority of its members, 
consider that the information provided by the Member State 
on a new psychoactive substance merits the collection of 
further information, this information shall be collated and 
presented by Europol and the EMCDDA in the form of a Joint 
Report (hereinafter the “Joint Report”).’ The Joint Report shall 
be submitted to the Council of the European Union, the 
European Medicines Agency (EMA) and the European 
Commission.
In May 2015 the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) and Europol examined the 
available information on the new psychoactive substance 
1-phenyl-2-(1-pyrrolidinyl)-1-pentanone, commonly known as 
α-pyrrolidinovalerophenone (α-PVP), through a joint 
assessment based upon the following criteria:
1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information 
collected on α-PVP satisfied all criteria (1 to 6). The two 
agencies therefore concluded that sufficient information had 
been accumulated to merit the production of a Joint Report on 
α-PVP as stipulated by Article 5.1 of the Council Decision.
I 2. Information collection process
In compliance with the provisions of the Council Decision, on 
27 May 2015 the EMCDDA and Europol launched a procedure 
for the collection of information on α-PVP, in order to prepare 
the Joint Report. The information was collected mainly 
through the Reitox National Focal Points in the Member 
States, Turkey and Norway, and the Europol National Units. In 
addition, the EMA collected information through the national 
competent authorities responsible for human and veterinary 
medicinal products in the Member States, Norway, Iceland 
and Liechtenstein. The EMA also provided information as 
relevant to the centralised procedure for authorising medicinal 
products. The information collection process was largely 
concluded by 8 July 2015; additional information and 
(1) OJ L 127, 20.5.2005, p. 32.
clarifications from some countries were received up to four 
weeks after this date.
Information provided to Europol
Europol asked the Europol National Units to provide 
information on:
n  the level of α-PVP production in their country;
n  the level of α-PVP distribution in their country;
n  the level of α-PVP trafficking in their country, for internal, 
transit or export purposes;
n  the number of seizures of α-PVP in their country, the total 
amount of the seizures, country of origin, details on the 
physical forms (including photos);
n  the role of organised crime, or criminal groups, in the 
production, distribution and trafficking of α-PVP in their 
country; and,
n  any known aspect of violence and/or money laundering 
relating to the production and trafficking of α-PVP.
Europol received responses from 19 Member States (2).
Information provided to the EMA
According to Article 5.3 of the Council Decision, the EMA 
requested that the national competent authorities responsible 
for human and veterinary medicinal products in the Member 
States and in Norway, Iceland and Liechtenstein provide 
information on whether:
n  the new psychoactive substance α-PVP has obtained a 
marketing authorisation;
n  the new psychoactive substance α-PVP is the subject of an 
application for a marketing authorisation; and,
n  a marketing authorisation that had been granted in respect 
of the new psychoactive substance α-PVP has been 
suspended.
Twenty-one countries provided a response to the EMA’s 
request regarding human and/or veterinary medicinal 
products (3). The EMA also provided information as relevant to 
the centralised procedure for authorising medicinal products.
(2)  In alphabetical order: Belgium, Bulgaria, Croatia, Cyprus, the Czech Republic, 
Estonia, France, Finland, Germany, Hungary, Italy, Latvia, Lithuania, 
Luxembourg, Poland, Romania, Slovakia, Slovenia and Spain.
(3)  Austria, Belgium, the Czech Republic, Estonia, Finland, Iceland, Ireland, 
Poland, Spain, Sweden and the United Kingdom provided a response in 
relation to human and veterinary medicinal products. Croatia, Greece and 
Italy provided a response in relation to human medicinal products. France, 
Germany, Hungary, Latvia, the Netherlands, Portugal and Slovenia provided a 
response in relation to veterinary medicinal products.
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Furthermore, in anticipation of Article 7.3 of the Council 
Decision in relation to the manufacturing of medicinal 
products in the European Union, the EMA also requested 
information on whether the new psychoactive substance 
α-PVP is used to manufacture a medicinal product:
n  that has been granted a marketing authorisation;
n  for which an application has been made for a marketing 
authorisation; and,
n  for which a marketing authorisation has been suspended 
by a competent authority.
Twenty-one countries (4) provided a response. The EMA also 
provided information as relevant to the centralised procedure 
for authorising medicinal products.
Information provided to the EMCDDA
The EMCDDA collected data through:
1.  a structured questionnaire to the Reitox National Focal 
Points. The EMCDDA received replies from the 28 Member 
States, Turkey and Norway;
2.  information previously provided to the European Union 
(EU) Early Warning System, including EMCDDA–Europol 
Reporting Forms, Progress and Final Reports; 
3.  a specific information request to the World Health 
Organization on whether or not α-PVP is under assessment 
by the United Nations system; and,
4.  a search of open source information that included: 
scientific and medical literature; official reports; grey 
literature; Internet drug discussion forums and related 
websites (hereafter, ‘user websites’); and online vendors 
selling α-PVP. 
Thus, the information included in sections 3.2.1, 3.3 and 
Annex of the Joint Report was provided by Europol, while the 
EMCDDA provided information included in sections 3.1, 3.2.2, 
3.4, 3.5, 3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part). The 
information included in sections 3.8.3 (in part), 4.1, 4.2 and 
4.3 was provided by the EMA. The conclusion of the Joint 
Report was prepared and agreed by the EMCDDA and 
Europol, the two agencies responsible for the report.
(4)  Austria, Belgium, the Czech Republic, Estonia, Finland, Iceland, Ireland, 
Poland, Spain, Sweden and the United Kingdom provided a response in 
relation to human and veterinary medicinal products. Croatia, Greece and 
Italy provided a response in relation to human medicinal products. France, 
Germany, Hungary, Latvia, the Netherlands, Portugal and Slovenia provided a 
response in relation to veterinary medicinal products.
I  3.  Information required by Article 5.2 of the Council Decision
The order and titles of subsections 3.1 to 3.8 and section 4 
below are as they appear in Article 5.2(a) to (h) and Article 
5.3(a) to (c) of the Council Decision; sections are cross-
referenced with those set down in the Council Decision.
I 
3.1.  Chemical and physical description, including the 
names under which the new psychoactive 
substance is known (Article 5.2(a) of the Council 
Decision)
Chemical description and names
α-PVP is a synthetic derivative of the naturally occurring 
substance cathinone, which is internationally controlled (5), 
and one of the psychoactive principles in khat (Catha edulis 
Forsk). α-PVP was first described in 1963 in the patent 
literature on α-pyrrolidino valerophenones (Wander, 1963) 
and on α-pyrrolidino ketones (Thomae, 1963).
All synthetic cathinone derivatives monitored by the EMCDDA 
through the EU Early Warning System are either N-alkylated or 
the nitrogen atom is part of a pyrrolidine ring, which is the 
case with α-PVP. Unlike many cathinone derivatives, α-PVP is 
not substituted on the phenyl ring.
Pyrrolidine derivatives, such as α-PVP, can be regarded as a 
subset of cathinone derivatives that share the same structural 
skeleton as pyrovalerone, prolintane and MDPV (Figure 1). 
α-PVP is also a metabolite — the desmethylated analogue 
— of pyrovalerone (1-(4-methylphenyl)-2-(1-pyrrolidinyl)
pentan-1-one), which is internationally controlled (6). α-PVP is 
the beta-keto derivative of prolintane (1-(1-benzylbutyl)
pyrrolidine), a noradrenaline-dopamine reuptake inhibitor 
developed in the 1950s. The methylenedioxy derivative of 
α-PVP — MDPV (7) — was risk-assessed by the Scientific 
Committee of the EMCDDA in 2014 (8). 
Pyrrolidino ketones such as α-PVP contain a stereogenic 
centre, thus allowing for the existence of a pair of 
(5)  Listed in Schedule I of the 1971 United Nations Convention on Psychotropic 
Substances.
(6)  Listed in Schedule IV of the 1971 United Nations Convention on Psychotropic 
Substances. 
(7)  1-(1,3-Benzodioxol-5-yl)-2-pyrrolidin-1-yl-pentan-1-one or 
methylenedioxypyrovalerone.
(8)  EMCDDA (2014), Report on the risk assessment of 1-(1,3-benzodioxol-5-yl)-2-
(pyrrolidin-1-yl)pentan-1-one (MDPV) in the framework of the Council Decision 
on new psychoactive substances, Publications Office of the European Union, 
Luxembourg, May 2014.
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enantiomers. There is no information on the isomeric 
composition of the samples of α-PVP detected within the EU, 
which in part may reflect the fact that stereochemical analysis 
is not routinely undertaken in forensic laboratories.
The most common substitution of alpha-pyrrolidinophenones 
is a side chain at the alpha carbon. Lower and higher 
homologues of α-PVP monitored by the EMCDDA are: 
alpha-pyrrolidinopropiophenone (α-PPP), 
alpha-pyrrolidinobutyrophenone (α-PBP), 
alpha-pyrrolidinohexanophenone (α-PHP), 
alpha-pyrrolidinoenanthophenone (α-PEP or PV8), 
alpha-pyrrolidinooctanophenone (α-POP or PV9) and 
alpha-pyrrolidinononaphenone (α-PNP) (9). 
α-PVP is the common name for alpha-
pyrrolidinovalerophenone. The systematic IUPAC name for 
α-PVP is (RS)-1-phenyl-2-(1-pyrrolidinyl)-1-pentanone.
Additional chemical synonyms reported are:
1-phenyl-2-(1-pyrrolidinyl)-1-pentanone
1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one
2-pyrrolidin-1-yl-1-phenylpentan-1-one 
2-(pyrrolidin-1-yl)phenylpentan-1-one
2-pyrrolidinovalerophenone
(9)  The origin for the common name is indicated by underlining the relevant 
letters in the systematic chemical name.
α-pyrrolidinopentiophenone
2-(1-pyrrolidinyl)-valerophenone
1-fenyyli-2-(1-pyrrolidinyyli)-1-pentanoni (Finnish)
α-pyrrolidiinivalerofenoni (Finnish)
α-pyrrolidinovalerophenon (German)
1-phenyl-2-(pyrrolidin-1-yl)pentan-1-on (German)
Common names or code names for α-PVP have also been 
reported: alfa-PVP, a-PVP, A PVP, PVP (code name also used 
for polyvinylpyrrolidone, a polymer commonly called 
polyvidone or povidone), PV (code name used for 
pyrovalerone), alpha-2, α-2, β-ketone-prolintane, prolintanone, 
desmethyl pyrrolidinovalerophenone and O-2387. The code 
name O-2387 originated in research published by Meltzer et 
al., 2006. 
The following street names have also been reported for α-PVP: 
‘grind’ (Belgium), ‘flakka’ (Croatia, Cyprus, the United Kingdom 
and Turkey), ‘gravel’ (Cyprus and Turkey), ‘crystal love’ 
(Finland), ‘Pure NRG’ (Germany), ‘Snow Blow’ (Ireland) and 
‘vanilla sky’ (Malta). 
Finally, the following products labelled ‘legal high’ have been 
reported to contain α-PVP: ‘Yayo soft’, ‘Yayo experimental’ and 
‘1NRG’ (Belgium); ‘Ocean Breath’ (Cyprus); ‘Guarana Coco 
jumbo’, ‘Cherry Coco jumbo’, ‘Iloveparade’ and ‘Sensation’ (the 
Czech Republic); ‘NRG3’, ‘Energy 3’ and ‘PV-11’ (France); ‘Pure 
NRG’ (Germany); ‘A-1 PUP’ (Italy); ‘E21’, ‘G-Y’, ‘S1 Turbo’ and 
‘GIE-ES M’ (Poland); ‘Sextacy’, ‘Bloom’, ‘Quick Silver’, ‘Formula 
FIGURE 1.
The molecular structure, weight and monoisotopic mass of α-PVP. The molecular structure for pyrovalerone, prolintane and 
MDPV are provided for comparison. Chiral centres are denoted by an asterisk on the molecular structures below
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3’, ‘Ivory’ and ‘Vanila Sky’ (Portugal); ‘Doves’, ‘Fire Ball’, ‘Green 
Speed’, ’Knock out’, ‘Max’, ‘Speedway’, ‘Total speed’ and ‘Ultra 
Violet Exclusive’ (Slovakia); and ‘NRG-3’, ‘Energy-3 (NRG-3)’ 
and ‘Spellweaver’ (the United Kingdom). Some of these 
products are marketed as ‘research chemicals’, ‘bath salts’, 
‘plant food’ or ‘insect repellents’ in order to circumvent 
legislation.
Chemical Abstract Service (CAS) registry numbers:
14530-33-7 free base
5485-65-4 hydrochloride salt
14859-27-9 tartrate salt
14859-28-0 maleate salt 
14995-79-0 citrate salt
100175-06-2 hydrogen maleate
16121-74-7 sulfate salt
13415-49-1 sulfate salt (1:1)
1346599-00-5 D
8
-free base
1781744-06-6 D
8
-hydrochloride salt
The REACH registered substances database hosted by the 
European Chemicals Agency (ECHA) was searched using the 
CAS registry numbers listed above. The searches returned no 
results.
Physical description
The hydrochloride salt of α-PVP is described as a white or 
off-white, odourless crystalline powder, with a melting point of 
161.3oC (10). It is reported to be soluble in PBS (~10mg/ml, 
pH7.2), in EtOH (~20mg/ml), in DMSO (~10mg/ml) and in 
DMF (~3mg/ml).
Information provided from seizures and collected samples 
reported by the Member States have usually noted the 
presence of α-PVP in powder form. α-PVP has also been 
detected in: tablets, powder-filled capsules, vegetable 
material, liquids, blotters (small pieces of paper impregnated 
with α-PVP for sublingual/buccal administration) and jelly 
gums. 
A more detailed description of α-PVP seizures and collected 
samples that have been reported can be found in sections 
3.2.1 and 3.2.2.
(10)  Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG), 
‘Monograph on α-PVP’. Available at: www.swgdrug.org/Monographs/a-PVP.pdf
I
 3.2.  Information on the frequency, circumstances 
and/or quantities in which a new psychoactive 
substance is encountered, and information on 
the means and methods of manufacture of the 
new psychoactive substance (Article 5.2(b) of 
the Council Decision)
It is important to note that some of the data reported to 
Europol (section 3.2.1) may overlap with the data reported to 
the EMCDDA (section 3.2.2).
3.2.1. Information provided to Europol
Europol received replies from 19 Member States (Belgium, 
Bulgaria, Croatia, Cyprus, the Czech Republic, Estonia, France, 
Finland, Germany, Hungary, Italy, Latvia, Lithuania, 
Luxembourg, Poland, Romania, Slovakia, Slovenia and Spain). 
The level of production
Hungary reported that α-PVP was detected in two tableting 
sites that were dismantled in 2013 and 2014. It must be noted 
that the synthesis of α-PVP did not take place at those sites. 
The site dismantled in 2013 was a tableting unit where 
pentedrone (11) tablets were produced; 24 908 tablets 
containing pentedrone and 800 g of α-PVP in powder form 
were seized (Figure 1 of the Annex). In 2014 the Hungarian 
police dismantled a tableting site where pentedrone tablets 
were also produced. In the storage location linked to this site, 
1.5 kg of α-PVP in powder form was seized (Figure 2 of the 
Annex). According to the Hungarian police, in both cases 
suspects intended to produce tablets using the α-PVP powder. 
Poland reported the seizure of two illicit production sites 
synthesising α-PVP. The first production facility, where 
brephedrone (12) was also manufactured, was seized in July 
2013 in Chorzow (Figure 3 of the Annex). Approximately 50 kg 
of α-PVP was produced in this site, which was destined both 
for the domestic market and to be exported. The second 
synthetic drug production facility, dismantled in October 2014 
in Krakow, also produced brephedrone and NEB 
(N-ethylbuphedrone). The amount of α-PVP and brephedrone 
seized totalled 4.5 kg. According to the Polish authorities, both 
cases were linked to a local group of ‘football hooligans’. The 
synthesis was supervised by trained chemists, and the 
laboratories were operated by suppliers, producers and 
distributors of chemicals. The companies involved operated 
their own websites offering the sale and distribution of those 
substances across Poland.
(11)  2-Methylamino-1-phenyl-1-pentanone; another synthetic cathinone 
derivative.
(12) 4-Bromomethcathinone; another synthetic cathinone derivative.
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The level of distribution
Seizure data reported to Europol suggest that α-PVP has been 
present in the EU drug market since at least 2012. With the 
exception of the synthetic drug production in Poland noted 
above, bulk quantities of α-PVP are mainly imported to the EU 
from China and further distributed from the Member States. 
The Czech Republic reported a case where α-PVP was 
shipped from there to another country outside the EU.
The earliest reported seizures of α-PVP were in 2012 
(Belgium, Cyprus, Finland and Latvia). Eleven Member States 
reported seizures for 2015 (Croatia, the Czech Republic, 
Finland, France, Germany, Hungary, Latvia, Lithuania, 
Luxembourg, Romania and Spain). 
In total, over 295 seizures in powder or crystalline powder form 
were reported, totalling over 370 kg of α-PVP (13). Most of the 
seizures were described as white or off-white in colour, but in 
one case from Spain the powder was described as ‘black rock 
powder’. Individual seizures ranged from low quantities of less 
than one gram up to quantities greater than one kilogram 
reported by seven Member States (Belgium, the Czech 
Republic, Finland, France, Hungary, Lithuania and Spain). The 
largest seizures were reported by Spain, where 259 kg of 
α-PVP was seized at Barcelona airport in one day, in April 2015.
Three Member States reported seizures of tablets containing 
α-PVP: the Czech Republic (160 tablets sold as MDMA, see 
Figure 4 of the Annex), Hungary (454 tablets in addition to the 
seizure conducted at the tableting site mentioned above) and 
Romania (two tablets). Packages containing α-PVP were 
seized in Slovakia (see Figure 5 of the Annex) and in Spain. In 
2015 Spain also reported a case with two jelly gums 
containing α-PVP.
Croatia reported that α-PVP is imported for personal use by 
young people, especially foreign tourists, who travel to Croatia 
for music festivals and other similar activities.
The level of trafficking
Information related to trafficking routes was provided by seven 
Member States (Bulgaria, France, Germany, Latvia, 
Luxembourg, Slovakia and Spain). See Table 1 for information 
on trafficking routes.
Poland is indicated as a country of origin in one case, which 
may be linked to the synthetic drug production facilities 
dismantled by the Polish authorities. In 10 of the 11 cases 
where trafficking route information was provided, China was 
noted as the source country for α-PVP. Germany and France 
would appear to be transit points in the EU, possibly due to the 
(13)  These figures do not include α-PVP seized by the Polish authorities on the 
two illicit drug production sites mentioned above.
location of air-freight hubs. The large quantities of α-PVP 
seized in or en route to Spain suggest that Spain may be an 
important point in the distribution chain of α-PVP. 
Romania reported that the main source country for 
importation of α-PVP is China, mainly via postal mail parcels.
The Czech Republic reported that α-PVP is imported using 
postal mail shipments and courier services.
3.2.2. Information provided to the EMCDDA
The EMCDDA received responses from the 28 Member States, 
Turkey and Norway. Of these, 26 Member States (14), Turkey 
and Norway reported detections of α-PVP (15).
According to reports to the EMCDDA, α-PVP has been present 
on the EU drugs market since 2011, although information 
published in the literature indicates that it was detected in 
Germany in 2005 (Westphal et al., 2005).
(14)  All Member States with the exception of Bulgaria and Romania. Note that the 
Bulgarian and Romanian Europol National Units reported the detection of 
α-PVP to Europol (section 3.2.1).
(15)  ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples that are analytically confirmed. Seizure 
means a substance available (seized) through law enforcement activities 
(police, customs, border guards, etc.). Collected samples are those that are 
actively collected by drug monitoring systems (such as test purchases) for 
monitoring and research purposes. Biological samples are those collected from 
human body fluids (urine, blood, etc.) and/or specimens (tissues, hair, etc.).
TABLE 1
Summary of α-PVP trafficking routes. The asterisk indicates 
the place where the seizure was made
Origin Transit Destination Comment
Poland Slovakia* Czech Republic Weight not specified
China Luxembourg* Germany 54 g in postal parcel
China – Bulgaria* 2 g in postal parcel
China – Latvia* Postal parcel (weight not 
specified)
China France* Spain 50 kg in transit at Roissy 
Airport, Paris
China France* Spain 1 kg in transit at Roissy 
Airport, Paris
China Germany* Austria 248 g in transit at 
Frankfurt Airport
China Germany* United Kingdom 171 g in transit at Munich 
Airport
China Germany* Sweden 10 g in transit at Frankfurt 
Airport
China – Germany* 4 g seized at Frankfurt 
Airport
China – Spain* 259 kg seized at 
Barcelona Airport 
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Seizures
Twenty-six Member States (all Member States with the 
exception of Bulgaria and Romania), Norway and Turkey 
reported seizures (16) of α-PVP to the EMCDDA. 
Overall, in excess of 5 200 seizures have been reported, with eight 
countries reporting more than 100 seizures each: the United 
Kingdom (1 094), Poland (938), Finland (787), Slovakia (502), 
Sweden (451), Ireland (336), Hungary (313) and Turkey (256). 
In 2011, after the first seizure of α-PVP was reported by 
France (see section 3.6), at least 38 additional seizures were 
reported in 17 countries: Austria, Belgium, the Czech 
Republic, Denmark, Estonia, Germany, Greece, Finland, 
Hungary, Ireland, Italy, Lithuania, Spain, Sweden, Slovakia, 
Turkey and the United Kingdom (17).
α-PVP has typically been seized in powder form (reported by 
all countries where α-PVP was detected). Over 750 kg of 
powder has been seized in total, with eight countries reporting 
seizures over 10 kg: Spain (312 kg), the Netherlands (140 kg), 
France (81 kg), Ireland (63 kg), the United Kingdom (62 kg), 
Hungary (24 kg), Finland (24 kg) and Poland (17 kg). Of these, 
the biggest single seizure occurred on 9 April 2015 in Spain, 
when the Spanish National Customs Surveillance Service 
seized almost 260 kg of α-PVP in 13 containers at Barcelona 
Airport, delivered from China. Two other single significant 
seizures also took place in Spain in 2015, with over 20 kg and 
5 kg of powder seized. 
Thirteen countries reported seizures of tablets (Slovakia, 
Hungary, Finland, the Czech Republic, Latvia, Turkey, Sweden, 
Norway, Spain, Poland, Belgium, Italy and France) (18) 
amounting to over 12 400 units. Of those, three countries 
reported seizures of over 1 000 tablets: Slovakia (7 157), 
Hungary (3 768) and Finland (1 136). The United Kingdom 
reported three seizures of powder-filled capsules.
Seven countries (Lithuania, the United Kingdom, Hungary, 
Slovakia, France, Sweden and Poland) (19) have reported small 
seizures (< 150 g) of vegetable material containing α-PVP, 
sometimes also containing synthetic cannabinoids. Three 
countries (Finland, Sweden and Poland) (20) have seized small 
quantities (< 150 ml) of liquids containing α-PVP. Austria 
reported a single seizure of 68 paper doses (also known as a 
(16)  Many ‘seizures’ relate to individual case-level data, however, some data 
provided to the EMCDDA are aggregated at the country level. Some of the 
data from the United Kingdom are reported as ‘records’, where several 
records may come from the same case. Data are drawn from the Joint 
Report Questionnaires and data provided in the bi-annual data gathering 
(EU EWS progress and final reports) and from individual Reporting forms 
submitted on an ad hoc basis.
(17) Countries are listed in alphabetical order.
(18) Countries are listed in decreasing order of number of tablets seized.
(19) Countries are listed in decreasing order of quantity of plant material seized.
(20) Countries are listed in decreasing order of quantity of liquids seized.
‘blotters’) containing DOC (21) and α-PVP, and Finland 
reported 16 seizures amounting to over 700 units of tablets/
blotters. Spain reported the seizure of two jelly gums in which 
α-PVP, amphetamine and caffeine were detected.
In around 35 % of the detections α-PVP was found in 
combination with other substances, including other 
cathinones (mainly MEC (22), MMC (23), pentedrone, 
MDPBP (24), ethylcathinone and MDPV), synthetic 
cannabinoids and a range of other new psychoactive 
substances (such as MPA (25), 5-MeO-MIPT (26), AMT (27) and 
2-DPMP (28)), substances that are internationally controlled 
and/or controlled at EU level (ketamine, PMMA (29), 
methoxetamine, MDMA, cocaine, amphetamine and heroin), 
benzodiazepines (etizolam, flubromazolam), and substances 
typically used as cutting agents and/or diluents such as 
benzocaine, lidocaine and caffeine. 
Information on purity, which was available from 16 seizures, 
ranged from 23 % (two seizures) to over 95 % (eight seizures).
Several countries reported α-PVP in powders contained in 
branded ‘legal high’ products with names such as: ‘Fire Ball’, 
‘Ultra Violet Exclusive’, ‘Pure NRG’, ‘Max’, ‘Total speed’, 
‘Energy-3 (NRG-3)’, ‘Guarana Coco jumbo’, ‘Cherry Coco jumbo’, 
‘Sensation’, ‘Iloveparade’, ‘Speedway’ and ‘A-1 PUP’. A full list of 
names is provided in section 3.1. In addition, the substance was 
found in two products branded ‘Green Speed’ and ‘Knock out’ 
containing plant material. Tablets containing α-PVP had the 
following markings: ‘Lacoste’, ‘Playboy’, ‘STADA1’ and ‘Homer 
Simpson’ (information available for seven seizures). These 
tablet findings may suggest that α-PVP is being sold as ecstasy. 
There were also unmarked tablets reported in a variety of 
colours. Some of these products were obtained through online 
shops (www.euphoriashop.sk, www.hypnotic.sk).
Collected samples
Eleven countries reported 50 samples collected from users or 
purchased on the Internet that contained α-PVP (30) (Austria, 
Belgium, the Czech Republic, Denmark, France, Hungary, the 
Netherlands, Slovenia, Spain, Turkey and the United Kingdom). 
Three countries reported powders sold as MDMA: Austria and 
Spain (one case each) and the United Kingdom (seven). In 
France, powders, capsules containing powder and pellets 
were sold either as methamphetamine, pentedrone and 
(21) 2,5-Dimethoxy-4-chloroamphetamine.
(22) Methylethcathinone (isomer not specified).
(23) Methylmethcathinone (isomer not specified).
(24) 3’,4’-Methylenedioxy-α-pyrrolidinobutyrophenone.
(25) Methylthienylpropamine.
(26) 5-Methoxy-N-methyl-N-isopropyltryptamine.
(27) α-methyltryptamine.
(28) 2-(Diphenylmethyl)piperidine.
(29) para-Methoxymethamphetamine.
(30) Countries are listed in alphabetical order.
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ethylphenidate or as branded ‘legal high’ products: ‘NRG-3’ 
(four samples), ‘PV-11’ (two) and ‘Ivory Wave Extreme’ (two). In 
the United Kingdom a sample sold as ‘NRG-3’ was also 
reported. In Spain a powder containing the substance was 
sold as ketamine in one case and a yellow jelly was collected 
from a user in another case. For more information on ‘legal 
high’ products that have been reported to contain α-PVP see 
section 3.1.
Biological samples
Eight Member States (Finland, France, Hungary, Ireland, Italy, 
Poland, Sweden and the United Kingdom) and Norway 
reported a total of 1 746 detections where α-PVP was 
analytically confirmed in biological samples.
These related to: 126 serious adverse events (105 deaths and 
21 acute intoxications); 393 cases related to patients 
undergoing drug treatment; 389 cases of persons suspected 
of driving under the influence of drugs; and 590 cases where 
detection was made by the police in persons suspected of 
having consumed drugs, or committed minor offences or 
crimes. A further 105 cases were detected through criminal 
justice drug screening programmes and the remaining 143 
were reported by the STRIDA project in respect to acute 
intoxications associated with new psychoactive substances.
In Finland α-PVP was analytically detected in 335 cases 
(including 37 deaths); in France six cases (two deaths and four 
non-fatal intoxications); in Hungary 352 cases (including 
19 deaths); in Ireland 116 detections (including four deaths); in 
Italy one case consisting of a non-fatal intoxication; in Poland 
there were 34 detections (including 21 deaths and one 
non-fatal intoxications); in Sweden 883 cases (including 
16 deaths, 14 non-fatal intoxications and one acute 
intoxication where the outcome is not known); in the United 
Kingdom eight detections (including six deaths); and finally in 
Norway 11 cases (all consisting of persons suspected of 
driving under the influence of drugs).
I 3.3.  Information on the involvement of organised crime in the manufacture or trafficking of the new psychoactive substance (Article 5.2(c) of the Council Decision)
Four Member States (Hungary, Latvia, Romania and Spain) 
provided information in relation to the involvement of 
organised crime in the manufacture or trafficking of α-PVP.
According to Hungarian authorities there are no ‘classical’ 
organised crime groups involved in the manufacture or 
trafficking of α-PVP.
Latvian authorities reported that since 2014 a new trend has 
been observed in relation to the market in new psychoactive 
substances. A Latvian organised crime group was involved in 
the mixing and posterior distribution of new psychoactive 
substances with plant material.
Romania reported that criminal groups are not involved in the 
trafficking of α-PVP.
Spain reported that they do not have any intelligence about 
α-PVP being linked to criminal groups.
Money laundering aspects
No information was received on money laundering in 
connection with the production and/or trafficking of α-PVP. 
Violence in connection with production, wholesale and 
distribution
No information was received on incidents of violence in 
connection with the production, wholesale and/or trafficking 
of α-PVP.
I 3.4.  A first indication of the risks associated with the new psychoactive substance, including the health and social risks, and of the characteristics of users — Article 5.2(d) of the Council Decision 
3.4.1. Serious adverse events reported to the EMCDDA
Case-level data for 140 serious adverse events (31) associated 
with α-PVP were reported to the EMCDDA by nine Member 
States (Finland, France, Germany, Hungary, Ireland, Italy, 
Poland, Sweden and the United Kingdom). These cases 
comprised 34 acute intoxications (32 non-fatal intoxications 
and two intoxications where the outcome was unknown (32)) 
(31)  Serious adverse event means any adverse event, whether analytically 
confirmed or not, that is associated with the consumption of a new 
psychoactive substance in a human that: results in death; is life-threatening; 
requires intensive treatment in an emergency room and/or requires 
hospitalisation; results in persistent or significant disability or incapacity; 
results in substance dependency or substance abuse; consists of 
a congenital anomaly or birth defect; or is an important medical event that 
may not be immediately life-threatening or result in death or hospitalisation 
but may jeopardise the patient or may require intervention to prevent one of 
the other outcomes listed above. An example of such events is: convulsions 
that do not result in hospitalisation.
(32)  I.e. in two cases it was not known if the acute intoxication related to a 
non-fatal or fatal intoxication.
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and 106 deaths (33). An overview of these data is presented 
below.
Acute intoxications
Case-level data for 34 acute intoxications associated with 
α-PVP were reported by six Member States: France (10 cases), 
Germany (two), Ireland (five), Italy (one), Poland (one) and 
Sweden (15). Thirty-two of the 34 cases were classified as 
non-fatal intoxications; in the remaining two cases the 
outcome of the intoxication was unknown (Germany, one case; 
Sweden, one case).
α-PVP was analytically confirmed in 21 of the 34 cases 
(section 3.2.2): France (four cases), Italy (one), Poland (one) 
and Sweden (15). In the remaining 13 cases α-PVP was not 
analytically confirmed: France (six cases), Germany (two) and 
Ireland (five); these latter cases have not been analysed 
further. Thus the overview below is based on data from the 21 
analytically confirmed cases.
It is important to note that case-level data on intoxications in 
Sweden are limited to a subset of cases where:
1.  α-PVP was the sole substance that was analytically 
identified (eight cases); or,
2.  α-PVP and ethanol were the only substances that were 
analytically identified (five cases); or,
3.  α-PVP and benzodiazepines (and metabolites of 
benzodiazepines) were the only substances that were 
analytically identified (one case); or,
4.  α-PVP and benzodiazepines (and metabolites of 
benzodiazepines) and ethanol were the only substances 
that were analytically identified (one case).
Overview of the analytically confirmed acute intoxications
The overview below provides some of the characteristics for 
the 21 analytically confirmed acute intoxications associated 
with α-PVP. Of these, 20 cases relate to non-fatal intoxications 
and one case relates to an intoxication where the outcome is 
unknown.
Demographics
Of the 21 analytically confirmed acute intoxications, 19 were 
male and two were female. The mean age of the male cases 
was 33.2 years (n=18; median 28.5 years); the two female 
cases were aged 23 and 25 years (n=2).
(33)  Cases that were believed by the EMCDDA to be duplicates (six deaths and 
three non-fatal intoxications) were not included in this total.
Substances analytically identified
Of the 21 analytically confirmed acute intoxications:
n  in eight cases reported by Sweden, α-PVP was the only 
substance that was identified (biological matrices unknown);
n  in five cases reported by Sweden, α-PVP and ethanol were 
the only substances that were identified (biological 
matrices not reported);
n  in one case reported by Sweden, α-PVP and 
benzodiazepines (and metabolites of benzodiazepines) 
were the only substances that were identified (biological 
matrices not reported);
n  in one case reported by Sweden, α-PVP and 
benzodiazepines (and metabolites of benzodiazepines) and 
ethanol were the only substances that were identified 
(biological matrices not reported);
n  in one case reported by France, α-PVP was the only 
substance that was identified in blood; urine drug 
screening identified ‘cannabis’;
n  in one case reported by France, it was not known if any 
other substances besides α-PVP were identified (biological 
matrices not reported);
n  in two cases reported by France, α-PVP was the only 
substance that was identified (biological matrices not 
reported);
n  in one case reported by Italy, α-PVP and THC were 
analytically identified in urine; and,
n  in one case reported by Poland, α-PVP was the only 
substance that was analytically identified in blood; 
pentedrone and alcohol were identified in urine.
Adverse symptoms and signs
Information on adverse symptoms and signs (34) reported 
from the 21 analytically confirmed acute intoxications were 
generally consistent with sympathomimetic toxicity. 
Adverse symptoms and signs were reported for each case. 
They included: tachycardia (15 cases); mydriasis (eight); 
hallucinations (six); agitation (five) or anxiety (two); tremor 
(five) or fasciculation (one) or tetany (one); hypertension (four); 
diaphoresis (four); hyperthermia (four); restlessness (three); 
chest pain (two); convulsions (two) or seizures (two); reduced 
consciousness (two); somnolence (two); numbness (two); 
distorted perception (one) or temporal/spatial disorientation 
(two); rhabdomyolysis (two); impaired liver function (one); 
impaired coagulation (one); difficulty in talking (one); paranoia 
(one); hyperventilation (one); hypoventilation (one); respiratory 
distress (one); muscular symptoms (one); and malaise (one).
(34) Adverse sign includes an abnormal laboratory finding. 
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Seriousness of the intoxications
Of the 21 analytically confirmed acute intoxications:
1.  in five cases the seriousness of the intoxication was 
classified as life-threatening, requiring treatment in 
hospital. Of these cases: in three cases α-PVP was the only 
substance that was identified; in one case α-PVP and 
benzodiazepines (and metabolites of benzodiazepines) 
were the only substances identified; in one case α-PVP and 
benzodiazepines (and metabolites of benzodiazepines) and 
ethanol were the only substances identified;
2.  in 11 cases the seriousness of the intoxication was classified 
as non-life-threatening but required treatment in hospital;
3.  in one case the seriousness of the intoxication was 
classified as involving persistent or significant disability or 
incapacity;
4.  in two cases the seriousness of the intoxication was 
classified as ‘moderate’ using an alternate national 
classification system (‘moderate’ is synonymous with 
pronounced or prolonged symptoms or signs); and,
5.  in two cases the seriousness of the intoxication was not 
reported.
Outcome of the non-fatal intoxications
Of the 20 analytically confirmed non-fatal intoxications:
1.  in 12 cases the outcome was classified as recovered/
resolved;
2.  in two cases the outcome was classified as recovering/
resolving;
3.  in four cases the outcome was classified not known; and,
4.  in two cases the outcome was not reported.
Route of administration
Of the 21 analytically confirmed acute intoxications:
1.  in six cases the route of administration was reported as 
snorting (nasal insufflation);
2.  in three cases the route of administration was reported as 
injection. In one of these cases it was reported that the 
substance was injected intravenously. The specific route of 
injection for the other three cases is not known;
3.  in two cases the route of administration was reported as 
oral administration;
4.  in one case the route of administration was reported as oral 
administration and injection; the specific route of injection 
was not reported; and,
5.  in nine cases the route of administration was not known.
Name of the substance/product used
Of the 21 analytically confirmed acute intoxications:
1.  in seven cases the name of the substance/product 
reported to be consumed was ‘MDPV’ (35);
2.  in three cases the name of the substance/product reported 
to be consumed was ‘alpha-PHP’;
3.  in two cases the name of the substance/product reported 
to be consumed was ‘NRG3’ or ‘energy 3’;
4.  in one case the name of the substance/product reported to 
be consumed was ‘crystal’;
5.  in one case the name of the substance/product reported to 
be consumed was ‘penta’ or ‘pentadrone’;
6.  in one case the name of the substance/product reported to 
be consumed was ‘APP’;
7.  in one case the name of the substance/product reported to 
be consumed was ‘3-MEC’;
8.  in one case the name of the substance/product reported to 
be consumed was ‘PV8’; and,
9.  in four cases the name of the substance/product reported 
to be consumed was not known.
Source
Information on where the patients had sourced the α-PVP was 
available in four cases: in three cases it was sourced from the 
Internet; in one case it was sourced from the Internet and a 
drug dealer.
Physical form
Information on the physical form of α-PVP used by the 
patients was available in four cases: all four used a powder 
(other characteristics of the powder were not reported).
Amount or dose administered
Information on the amount of substance administered by the 
patients was only available in two cases:
n  in one case the amount or dose administered was reported 
as ‘15–20 mg’ (oral);
n  in one case the amount or dose administered was reported 
as ‘ca. 330 mg’ (route not known).
Deaths
Case-level data for 106 deaths associated with the use of 
α-PVP were reported by seven Member States: Finland 
(37 cases), France (two), Hungary (19), Ireland (five), Poland 
(21), Sweden (16) and the United Kingdom (six). 
(35)  This includes one case where the substance consumed was reported as 
‘MDPVP’, which is a synonym of MDPV.
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α-PVP was analytically confirmed in 105 deaths. One death 
reported by Ireland was excluded from further analysis as it 
was not analytically confirmed. In addition, four deaths 
reported by Poland were also excluded from further analysis, 
as, beyond the fact that they were analytically confirmed, no 
further information on the cases is currently available. Thus 
the overview below is based on data from 101 analytically 
confirmed deaths.
Demographics
Of the 101 deaths, 81 (80.2 %) were male and 20 (19.8 %) 
were female. The mean age of the male decedents was 36.3 
years (n=66; median 33 years); the mean age of the female 
decedents was 35.4 years (n=20; median 34.5 years).
Number of deaths by year
Seventeen deaths occurred in 2012; 24 occurred in 2013; 
43 in 2014; and 15 in 2015. The year of death was not known 
for two of the deaths.
Cause of death
Preliminary review of the cause of death reported for the 101 
deaths suggests that:
n  in 23 cases α-PVP was reported as the cause of death 
(three cases) or was reported as a contributing factor (20);
n  in 26 cases the cause of death was reported as ‘not known’ 
— in some of these cases the investigation is ongoing;
n  in four cases the cause of death was reported as due to 
drug intoxication (no further details available);
n  further analysis of the data are required for the remaining 
48 cases in order to determine what role, if any, α-PVP 
played in the deaths.
3.4.2.  Serious adverse events identified in open source 
information
Case-level data for 33 serious adverse events associated with 
α-PVP were identified from searches of open source 
information (OSI) (Eiden et al., 2013; Dragogna et al., 2014; 
Hasegawa et al., 2014; Marinetti and Antonides, 2013; 
Minakata et al., 2014; Namera et al., 2013; Namera et al., 2014; 
Richards-Waugh et al., 2013; Saito et al., 2013; Sellors et al., 
2014; Shanks et al., 2013; Sykutera et al., 2015; Yoshida et al., 
2014) (36). These comprised three non-fatal intoxications and 
30 deaths. One of the deaths is believed to be reported in two 
separate reports and so the total number of deaths is believed 
(36)  In addition, Papsun (2015) reports 28 postmortem cases where α-PVP was 
analytically identified. No further details are available on these cases.
to be 29. Of these cases, one non-fatal intoxication (Eiden et 
al., 2013) and two of the deaths (Eiden et al., 2013; Sykutera 
et al., 2015) were also reported to the EMCDDA by the 
Member States and are excluded from the analysis below. 
Details of the two non-fatal intoxications are provided in 
Dragogna et al., 2014 and Namera et al., 2014. A total of 
27 deaths that occurred outside the EU were identified.
Briefly, a cause of death has been reported for 13 of the 
27 deaths that occurred outside the EU:
n  in seven cases α-PVP was considered the cause of death 
or a contributing factor (no other substances were 
analytically identified in four of these cases). It is important 
to note that in two of the seven cases the deaths occurred 
following responses to the aggressive behaviour shown by 
the decedents. In one case the confrontation resulted in 
the decedent being shot by the police, in one other case 
the confrontation led to prolonged restraint, which was 
reported to have contributed to the death;
n  in four cases polydrug intoxication or overdose where 
another substance was considered the primary cause of 
death was reported;
n  in one case the cause of death was related to a shooting by 
police; and,
n  in one case the cause of death was related to hanging.
3.4.3. Pharmacology
Mode of action
Overview
Published data on the pharmacological mode of action of 
α-PVP appear to be limited to eight non-clinical studies (37). All 
but one of these studies (Meltzer et al., 2006) (38) were 
undertaken as a result of α-PVP emerging on the drug market; 
notably, seven of them have been published since 2014 
(Aarde et al., 2015; Gatch et al., 2015; Kaizaki et al., 2014; 
Marusich et al., 2014; Naylor et al., 2015; Rickli et al., 2015; 
Watterson et al., 2014a).
Taken together, the data from these studies are suggestive 
that α-PVP is likely to be a potent psychostimulant in humans, 
an observation that is consistent both with reports of serious 
adverse events and with subjective experiential reports from 
(37)  Non-clinical study means a scientific study that is conducted either in silico, 
in vitro, or in vivo in animals.
(38)  In respect to data on pharmacology of α-PVP, the study by Meltzer et al., 
2006 was limited to investigating the in vitro characteristics as an inhibitor of 
the dopamine (DAT), norepinephrine (NET), and serotonin (SERT) 
transporters.
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users on discussion forums. The data are also suggestive of 
abuse liability and dependence potential in humans.
Further research is required in order to have a more detailed 
understanding of the mode and mechanism of action of α-PVP 
(including its two enantiomers), including abuse liability and 
dependence potential, and how this relates to humans. This 
should also include the study of the pharmacological effects 
of α-PVP on other neurotransmitter systems and the 
pharmacological effects of the metabolites of α-PVP.
In vitro data
Data from in vitro transporter assays by Marusich et al., 2014 
showed that α-PVP was a potent inhibitor of dopamine uptake 
at the dopamine transporter (DAT) (IC
50
 12.8±1.2) and 
norepinephrine uptake at the norepinephrine transporter 
(NET) (IC
50
 14.2±1.2), whereas it was a much weaker inhibitor 
of serotonin uptake at the serotonin transporter (SERT) (IC
50
 
>10,000 nM) (Table 2). These data confirmed the findings 
reported by Meltzer et al., 2006 and Rickli et al., 2015. 
Interestingly, α-PVP appeared to share similar effects with 
3,4-methylenedioxypyrovalerone (MDPV).
Overall, the data from the transporter assays show that: 
1.  α-PVP is a potent and selective inhibitor of the 
catecholamine uptake at DAT and NET;
2.  α-PVP does not act as a transporter substrate, i.e. it does 
not cause neurotransmitter release;
3.  α-PVP is a more potent inhibitor of DAT and NET than the 
classical stimulants cocaine and amphetamine; and,
4.  α-PVP and MDPV both exhibit catecholamine-transporter 
selective activity and similar potencies in respect to 
inhibition of DAT and NET.
Animal data
Data from locomotor studies in mice conducted by Marusich 
et al., 2014 showed that α-PVP at 3.0 and 10.0 mg/kg given by 
intraperitoneal injection (IP) produced significant increases in 
locomotion compared to saline over a 60 minute test session; 
a dose of 1 mg/kg IP only produced a significant increases in 
locomotion between 20–50 minutes of the test session. While 
α-PVP was less potent than MDPV in stimulating locomotion, 
the two substances showed similar efficacy, as a higher dose 
of α-PVP was able to increase locomotion to at least the same 
level. Both α-PVP and MDPV were more potent at stimulating 
locomotion than cocaine (39).
Data from Marusich et al., 2014 also showed that 
pretreatment with 0.03 mg/kg IP (40) of the dopamine D1 
receptor antagonist SCH23390 significantly decreased 
locomotor activity in mice when given at a 3 mg/kg dose of 
α-PVP. This finding suggests that the D1 receptor may mediate 
at least some of the locomotor effects of α-PVP consistent 
with previous findings published by Kaizaki et al., 2014. Data 
from previous studies have shown that the activation of the 
D1 receptor is implicated in the psychomotor and/or 
behavioural effects of stimulants such as cocaine, 
amphetamine, cathinone, and mephedrone (Marusich et al., 
2014). Data from locomotor studies in rats conducted by 
Aarde et al., 2015 also show that, compared to saline, peak 
locomotor responses to α-PVP occurred at 1.0 mg/kg IP and 
lasted for ~2 hours; similar findings were also reported for 
MDPV. Data from a functional observational battery in mice 
conducted by Marusich et al., 2014 showed that α-PVP 
produced psychostimulant effects similar to the classical 
stimulants cocaine and methamphetamine. In addition, α-PVP 
(39) Data for cocaine were derived from Baumann et al., 2013.
(40) Intraperitoneal.
TABLE 2
Effects of MDPV, α-PVP, α-PBP, α-PPP, cocaine, and amphetamine on inhibition of [3H] transmitter uptake at DAT, NET and 
SERT in rat brain synaptosomes. Data are expressed as nM concentrations (mean±SD) for n=3 experiments performed in 
triplicate
Test drug
[3H]Dopamine uptake, 
IC
50
 at DAT (nM) 
[3H]Norepinephrine uptake, 
IC
50
 at NET (nM) 
[3H]Serotonin uptake, 
IC
50
 at SERT (nM) 
DAT/SERT ratio 
MDPV 4.1±0.6 25.9±5.6 3305±485 806
α-PVP 12.8±1.2 14.2±1.2 >10 000 >781
α –PBP 63.3±5.7 91.5±12.8 >10 000 >159
α –PPP 196.7±9.9 444.7±39.2 >10 000 >51
Cocaine (a) 211±19 292±34 313±17 1.5
Amphetamine (a) 93±17 67±16 3418±314 37
Note: 
(a)  Data for cocaine and amphetamine were derived from Baumann et al., 2013. Reproduced from Marusich et al., 2014.
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also induced exploration and flattened body posture. Studies 
in mice reported by Gatch et al., 2015 confirmed that α-PVP 
induced stimulant locomotor activity, conditioned place 
preference (inverted U-shaped dose effects), and fully 
substituted for discriminative stimulus effects in rats trained 
to discriminate between cocaine, methamphetamine and 
saline. An additional drug discrimination study confirmed that 
α-PVP fully substituted for methamphetamine (Naylor et al., 
2015). 
Metabolism
Data on the metabolism of α-PVP are presented in Hasegawa 
et al., 2014; Namera et al., 2014; Negreira et al., 2015; Sauer et 
al., 2009; Shima et al., 2014; Uralets et al., 2014; and Tyrkkö et 
al., 2013.
No studies were identified that have examined the 
pharmacological effects of the metabolites of α-PVP.
Abuse liability and dependence potential
Data on the dependence potential and abuse liability of α-PVP 
are limited to non-clinical studies. 
Data from a discriminative-stimulus effect study conducted by 
Naylor et al., 2015 showed that in rats trained to discriminate 
1.0 mg/kg of the classical stimulant methamphetamine from 
saline, α-PVP fully substituted for methamphetamine. α-PVP 
(ED
50
=0.7 mg/kg) was approximately 2.5 times less potent 
than methamphetamine (ED
50
=0.3 mg/kg) and 4.5 times 
more potent than cocaine (ED
50
 3.3 mg/kg). These data were 
consistent with α-PVP producing behavioural effects similar to 
those of methamphetamine.
Data from a study conducted by Watterson et al., 2014a that 
examined intracranial self-stimulation (ICSS) thresholds in 
rats showed that α-PVP at 1 mg/kg produced a significant 
maximal reduction in ICSS thresholds (~19 %) similar to 
methamphetamine (1 mg/kg ~20 %) and MDPV (0.5 mg/kg 
~18 %) (41). It was suggested that α-PVP might show abuse 
liability in humans. Studies in mice reported by Gatch et al., 
2015 confirmed that α-PVP exhibited induced conditioned 
place preference (inverted U-shaped dose effects), and that it 
fully substituted for discriminative stimulus effects in rats 
trained to discriminate between cocaine, methamphetamine 
and saline. Data from a study conducted by Aarde et al., 2015 
that examined intravenous self-administration of α-PVP in rats 
showed that it was readily self-administered, and equally 
potent and effective to MDPV, which suggested potential for 
abuse liability in humans.
(41) Data on MDPV from Watterson et al., 2014b.
3.4.4. Toxicology
No studies were identified that have examined the toxicology 
of α-PVP including its enantiomers; no studies were identified 
that have examined the toxicology of the metabolites of 
α-PVP. Data from serious adverse events associated with 
α-PVP are discussed above (see section 3.4.1).
3.4.5. Characteristics of users
Data on the characteristics of users of α-PVP are limited. 
Data reported by the Member States (42) and identified from 
open source information (e.g. Sundström et al., 2015 and 
Simonsen et al., 2015) suggests that α-PVP is used by 
recreational and high-risk drug users, including those who 
inject drugs.
It is important to note that it is not possible to confirm the 
specific substance(s) used from self-reported user 
experiences, nor the purity, dose/amount, etc. Analyses of 
new psychoactive substances or products containing them 
that are sold on the drug market have shown that the 
composition can differ both from that claimed by the retailer 
and over geographical areas and time. In addition, the 
information provided on user websites may not necessarily be 
representative of users of α-PVP in general and should be 
regarded as illustrative only.
Route of administration, dose, drug regimens and settings 
of use
Routes of administration include snorting, smoking/inhalation, 
injection, oral (ingestion), sub-lingual, rectal and mixed routes 
(oral and injection). 
Injection of α-PVP was stated in four of the acute intoxications 
reported by the Member States. Injection was also self-reported 
as a route of administration by the Finnish Drug Users’ Union, 
three users presenting at a French drug testing unit, and by an 
undisclosed number of users in online forums. Data from France 
and Finland related to analysis of discussion forums suggest 
that intravenous injection was a common route of injection. 
(42)  Including data from: serious adverse events reported to the EMCDDA, where 
details of the set or setting of administration were known; questionnaire 
responses from six users presenting at a drug testing organisation (SINTES, 
France); an online questionnaire completed by 1 385 people in Poland 
(I-Trend); reports from representatives of the Finnish Drug Users’ Union 
(FDUU); monitoring of self-reported user experiences posted in Internet 
discussion forums. This information was captured by several countries, in 
their native tongue. Briefly, in France, data was obtained from the systematic 
monitoring of three forums (902 discussions threads, four of which 
specifically related to i-PVP) and from a special project in French- and 
English-speaking forums (eight forums, two discussion threads on α-PVP); 
for Finland, two online discussion forums were monitored (www.paihdelinkki.
fi and psyvault.net); in Italy two cases were reported from discussion threads 
(in Italian, www.psychonaut.com).
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Data from Sundström et al., 2015 and Simonsen et al., 2015 
also suggest that α-PVP is being used by high-risk drug users. 
Simonsen et al., 2015 have shown that, in 2012, in eight of 162 
deaths in Finland (4.9 %) and in one of 255 deaths in Sweden 
(0.4 %) α-PVP was analytically identified. Sundström et al., 2015 
have shown that α-PVP was analytically identified in 13 out of 
34 (38 %) attendees of a drug treatment centre specialising in 
supporting intravenous drug users. Data reported by Ireland 
suggest that injection under the skin (‘skin-popping’) might also 
be a feature since a substance called ‘Snow Blow’, suspected to 
contain α-PVP, has been used in this manner. This suggestion is 
based on α-PVP analytical findings in high-risk drug users 
reporting that they use ‘Snow Blow’.
Snorting was the route used in seven of the serious adverse 
events reported to the EMCDDA and is the most frequently 
quoted route of administration in online discussion forums in 
France and Poland (89 % of 36 responders to the Polish 
I-Trend survey). Some users believe that smoking α-PVP (by 
vapourisation or using a pipe) increases ‘side effects’ (I-Trend, 
France).
Information from serious adverse events suggests that α-PVP 
may be used as part of polydrug regimens (data not shown).
Dose, re-dosing
The available data do not allow the identification of common/
typical doses of α-PVP. 
France reported a dose of 20–30 mg reported by two drug users 
that was injected intravenously. Data on the dose of α-PVP taken 
were available in two acute intoxications reported by the 
Member States. In one case a dose of 15–20 mg was orally 
taken, and in another case 330 mg was taken (route unknown).
Users in a Finnish discussion forum report re-dosing after 
30–120 minutes, since ‘the effects don›t last very long’, being 
sometimes as short-lived as 15 minutes, ‘so one has to take a 
new dose shortly after the previous one’. Interestingly, a user 
in an Italian Internet forum warns against re-dosing, 
suggesting that doing it two or three times in a short period of 
time brings about impulsive behaviour which results in 
continuous re-dosing (‘you can no longer stop’). Survey data 
from the Polish I-Trend project found that 17 % of 36 α-PVP 
users (n=6) reported a ‘strong craving to use more’ α-PVP 
after the initial dose. 
Settings of use
There is limited data on the settings of use for α-PVP. 
Survey data from the Polish I-Trend project found that, out of 
36 α-PVP users, 53 % took it at home (n=19) and 75 % with 
friends (n=27). Data from serious adverse events are 
suggestive of α-PVP being used in a range of settings 
including at home (seven deaths, Hungary and the United 
Kingdom) and in party contexts (two deaths, France and 
Hungary). 
Subjective effects
Data on the subjective effects of α-PVP are limited. 
Survey data from the Polish I-Trend project found that, out of 
36 α-PVP users, the substance is used to ‘get high’ (72 %, 
n=19) and ‘socialise/bond with others’ (66 %, n=24). 
‘Euphoria’ and ‘increased libido’ are mentioned in discussion 
forums (Finland, France). 
There are several reports of adverse effects occurring 
following self-reported consumption of α-PVP. Survey data 
from the Polish I-Trend project found that out of 36 α-PVP 
users, 53 % (n=19) reports of negative effects. Negative 
effects can include paranoia, intensive hallucinations, 
aggression and insomnia. According to the respondents, these 
adverse effects can persist for several days.
Availability, supply, price
Online vendors
A structured search by the EMCDDA of online vendors (43) of 
α-PVP on the surface web (44) identified 65 vendors that 
appeared to be based in, and/or claim to have a presence in, 
the EU (n=28 sites), the United States (n=13 sites), China 
(n=32 sites), India (n=3 sites) or Russia (n=6 sites). 
Seventeen of the sites only provided quantities and prices for 
α-PVP on application. Eleven of the sites listed prices but did 
not specify quantities. The remaining 37 sites listed quantities 
and prices. Briefly:
n  On these sites α-PVP was typically sold as a ‘research 
chemical’.
n  The minimum quantity offered was 1 g (n=16 sites) with a 
mean price of EUR 17.50 (EUR 12–24). 
n  The maximum quantity offered was 10 kg (n=4 sites) with a 
mean price of EUR 17 000. 
n  Most of the 37 sites offered quantities ranging from 1 g 
(n=16 sites) to 1 kg (n=21 sites).
n  The mean price for 1 g was EUR 17.50. 
(43)  This includes vendors that appear to be consumer-orientated as well as 
vendors, for example on business-to-business sites, that appear to be 
manufacturers and/or wholesalers. It excludes those selling α-PVP through 
online classified advertisements, social media and user websites.
(44)  The search of online vendors of α-PVP was performed on google.co.uk using 
three search strings: ‘buy a-PVP’, ‘buy alpha-PVP’ and ‘buy 
pyrrolidinopentiophenone’. For each of the search strings the first 100 results 
were recorded and the sites reviewed. The results of the three searches 
partially overlapped; duplicate sites were removed from the analysis. Each 
identified vendor site was then scored for information on warehouse 
location, quantities and prices, and substance marketing.
JOINT REPORTS I α-PVP
16 / 26
n  The mean price for 10 g (n=26 sites) was EUR 134.50 
(EUR 63–180) (EUR 13.45/g).
n  The mean price for 100 g (n=33 sites) was EUR 594.50 
(EUR 270–1 200) (EUR 5.94/g).
n  The mean price for 1 kg (n=30 sites) was EUR 2 490 
(EUR 1 260–3 600) (EUR 2.49/g). 
n  The mean price for 5 kg (n=9 sites) was EUR 10 500 
(EUR 4 545–12 000) (EUR 2.10/g).
n  The mean price for 10 kg (n=4 sites) was EUR 17 000 
(EUR 6 705–23 000) (EUR 1.70/g). 
Prices were listed in Euros (EUR) on 14 sites, in United States 
Dollars (USD) on 22 sites, and in Great British Pounds (GBP) 
on one site (45). 
Other information
Information reported by France suggests that α-PVP may not 
be as easily obtainable in France ‘by name’ as it might have 
been during 2013 when sales were made through Internet 
retailers that were accessible only by invitation.
In France it was reported that α-PVP was sold as MDMA, 
cocaine and amphetamine. In Ireland it is sold as cocaine or 
methamphetamine. It has also been reported as being sold by 
its own name. 
France provided detailed information on the source and price 
of some samples collected from users. Reported prices per 
capsule were EUR 15 and EUR 20, and between EUR 20–80 
per gram of powder (for more details see sections 3.4.2 and 
3.8.2). In most of the cases the products had been originally 
sourced from the Internet by the user, a dealer or a friend.
Prevalence of use
No prevalence surveys were identified that have examined the 
use of α-PVP in the general population. 
Data reported from the Polish I-Trend online questionnaire 
indicate that, among 1 074 respondents, α-PVP was the most 
recently used new psychoactive substance to be used by 
3.4 % (n=36) of the respondents (36 users, n=1 074). Of these, 
39 % had taken it at least 20 times in the previous year.
One study has analysed the frequency of α-PVP analytical 
findings in deaths of high-risk drug users in Nordic countries 
(Denmark, Finland, Norway, Sweden and Iceland) in 2012, and 
found it to be 4.9 % in Finland and 0.4 % in Sweden (Simonsen 
et al., 2015).
(45)  Prices listed in USD were converted to EUR according to the Google 
exchange rate on 27 July 2015 (USD 1 = EUR 0.90). Prices listed in GBP were 
converted to EUR according to the Google exchange rate on 28 July 2015 
(GBP 1 = EUR 1.41).
I 3.5.  Information on whether or not the new substance is currently under assessment, or has been under assessment, by the UN system (Article 5.2(e) of the Council Decision)
The World Health Organization is the specialised United 
Nations agency designated for the evaluation of the medical, 
scientific and public health aspects of psychoactive 
substances under the 1961 Single Convention on Narcotic 
Drugs and the 1971 Convention on Psychotropic Substances. 
On 27 June 2015 the World Health Organization informed the 
EMCDDA that α-PVP is currently not under assessment and 
has not been under assessment by the United Nations system.
I 3.6.  The date of notification on the Reporting Form of the new psychoactive substance to the EMCDDA or to Europol (Article 5.2(f) of the Council Decision)
The first official notification of α-PVP to the EMCDDA–Europol 
dates from April 2011, from the French National Focal Point. 
The Reporting Form details a seizure of 5 114 g of white 
powder, also containing pentedrone, that was seized on 
22 February 2011 by the French Customs authorities at 
Charles de Gaulle Airport in Paris. The identification and 
analytical characterisation was based on GC-MS (46) at the 
SCL laboratory of Paris (47).
α-PVP was added to the list of new psychoactive substances 
monitored by the EMCDDA and Europol through the EU Early 
Warning System and a profile of the substance was created on 
the European Database on New Drugs (EDND). Since then, 
analytical details and other information have been exchanged 
between the EMCDDA, Europol and the Member States on an 
ad hoc basis; the European Commission and the EMA have 
been kept duly informed.
I 3.7.  Information on whether or not the new psychoactive substance is already subject to control measures at national level in a Member State (Article 5.2(g) of the Council Decision)
Fifteen Member States (Estonia, Finland, France, Germany, 
Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Poland, 
Romania, Slovenia, Sweden and the United Kingdom), Turkey 
and Norway reported that α-PVP is controlled under drug 
control legislation.
(46)  Gas chromatography-mass spectrometry.
(47)  Service commun des laboratoires (SCL).
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n  In Estonia α-PVP was listed in Regulation No. 73 of the 
Minister of Social Affairs of 18 May 2005 on 2 June 2014.
n  In Finland α-PVP was listed in the Narcotics Act 373 of 
2008 on 30 December 2013.
n  In France α-PVP was added to the controlled narcotic 
substance list on 2 August 2012.
n  In Germany α-PVP was placed under schedule II (narcotics 
eligible for trade but not for medical prescription) of the 
Narcotic Substance Act, effective as of 17 July 2013.
n  In Greece α-PVP is considered to be controlled under law 
3459/2006 due to the fact that it has the same molecular 
weight and molecular formula as Metazocine, an opioid 
analgesic classified in Table C of this law.
n  In Hungary α-PVP is listed in Schedule A (psychotropic 
substances) of Act XXV of 1998 on human 
pharmaceuticals on 1 January 2015.
n  In Ireland α-PVP is covered by the generic definition of 
controlled cathinones included in the Misuse of Drugs Act.
n  In Italy α-PVP is also controlled generically, as a derivative 
of 2-amino-1-phenyl-1-propanone, under the Decree of the 
President of the Republic 309/90 of 29 December 2011.
n  In Latvia α-PVP is controlled generically according to 
Cabinet Regulation 847, ‘Regulations regarding narcotic 
substances, psychotropic substances and precursors to be 
controlled in Latvia’.
n  In Lithuania α-PVP is controlled as a cathinone derivative 
by an Amendment to the Law on the Control of Narcotic 
Drugs and Psychotropic Substances adopted in 2010.
n  In Poland α-PVP was listed in Schedule IV of the Act of 
24 June 2015 amending the Act of Counteracting Drug 
Addiction on 1 July 2015.
n  In Romania α-PVP is controlled by Law 143/2000 on 
preventing and combating trafficking and illicit drug use 
and it is listed in Table I of the law 339/2005 on the legal 
regime of plants, narcotic and psychotropic substances 
and preparations.
n  In Slovenia α-PVP was included by the Decree on 
amending the Decree on Classification of Illicit Drugs, 
Official Gazette of RS No. 45/2014 in July 2014.
n  In Sweden α-PVP came under the Narcotic Drugs Control 
Act on 1 February 2013.
n  In the United Kingdom α-PVP was included in the generic 
definition of substituted cathinone derivatives placed 
under the Misuse of Drugs Act 1971 in April 2010 and it is 
controlled as a class B drug.
n  In Turkey α-PVP is listed in the Law on Control of Narcotics 
No.2313 adopted on 22 March 2012.
n  In Norway α-PVP is covered by the generic definition of 
cathinones in the Norwegian list of narcotics.
Four Member States (Austria, Cyprus, Portugal and Slovakia) 
reported that α-PVP is controlled under legislation prohibiting 
the unauthorised supply of defined or qualifying new 
psychoactive substances. 
n  In Austria α-PVP is categorised as a member of the ‘amino 
phenyl ethanone’ (i.e. cathinone) generic group in the new 
psychoactive substances act.
n  In Cyprus α-PVP also falls under the generic definition of a 
cathinone under specific new psychoactive substances 
legislation as of 24 June 2011.
n  In Portugal α-PVP is listed as controlled under Decree-Law 
154/2013 of 17 April 2013.
n  In Slovakia α-PVP was listed as a ‘hazardous substance’ on 
1 October 2013.
In the Netherlands the sale of α-PVP in consumer amounts is 
treated as being a medicinal product and must comply with 
medicines legislation.
Eight Member States (Belgium, Bulgaria, Croatia, the Czech 
Republic, Denmark, Luxembourg, Malta and Spain) reported 
that α-PVP is not subject to control measures at the national 
level. Belgium and the Czech Republic reported that they have 
started the process to control the substance under drug 
control legislation.
I 3.8.  Further information (Article 5.2(h) of the Council Decision)
3.8.1.  The chemical precursors that are known to have 
been used for the manufacture of the substance
No information was reported by the Member States, Turkey or 
Norway about the chemical precursors or manufacturing 
methods used to make the α-PVP that has been detected 
within the EU. Methods for the production of α-PVP are 
documented in the scientific literature.
The synthesis of pyrovalerone and its derivatives was initially 
published by Wander (1963) and Thomae (1963). 
The synthesis of α-PVP was also described in 1967 in a patent 
on α-pyrrolidino ketones by Boehringer Ingelheim (1967). In 
that patent, α-PVP was prepared by adding pyrrolidine to a 
solution of α-chloro-valerophenone in benzene, accompanied 
by stirring. Synthesis of α-PVP by Meltzer et al., 2006 was 
achieved through the α-bromination of the intermediate 
ketone with the addition of pyrrolidine to yield α-PVP as a 
colourless solid. Casale et al., 2012 employed a similar 
synthetic method, reacting valeronitrinile with 
phenylmagnesium bromide to form 1-phenyl-1-pentanone, 
which was then brominated to form the intermediate alpha-
bromo ketone. 
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3.8.2.  The mode and scope of the established or 
expected use of the new substance
No studies were identified that have examined the mode and 
scope of established or expected use of α-PVP. Given the 
limited information currently available, the relevant 
information has been included in the previous sections.
3.8.3.  Other use of the new psychoactive substance 
and the extent of such use, the risks associated 
with this use of the new psychoactive substance, 
including the health and social risks
No information was provided by any Member State that 
indicated that α-PVP had any other use apart from in 
legitimate scientific research and in analytical reference 
materials.
From the available information, it does not appear that α-PVP 
is used in the manufacture of a medicinal product in the EU; 
however, the data collection is incomplete and some countries 
indicated that this information is not known.
Seven Member States (Austria, the Czech Republic, Estonia, 
Finland, Greece, Poland and Spain) provided information that 
α-PVP is not used to manufacture a medicinal product for 
human use. Six Member States (Belgium, Croatia, Ireland, 
Italy, Sweden and the United Kingdom) and Iceland replied 
that they did not know this information. Ten Member States 
(Austria, the Czech Republic, Estonia, Finland, France, 
Hungary, Latvia, Poland, Spain and the United Kingdom) 
provided information that α-PVP is not used to manufacture a 
medicinal product for veterinary use. Seven Member States 
(Belgium, Germany, Ireland, the Netherlands, Portugal, 
Slovenia and Sweden) and Iceland replied that they did not 
know this information. 
In addition, the EMA reported that it is not known if α-PVP is 
used in the manufacture of medicinal products for human or 
veterinary use in the EU. It is understood that the collection of 
such information is a challenge in the absence of an EU 
database on the synthetic routes of all medicinal products.
I 4.  Information from the EMA (Article 5.3 of the Council Decision)
I 4.1. Marketing authorisation
Twenty-one Member States responded to the EMA’s 
information request (section 2). They reported that the new 
psychoactive substance α-PVP has not obtained a marketing 
authorisation (48). The EMA also reported that the new 
psychoactive substance α-PVP has not obtained a marketing 
authorisation through the centralised procedure for 
authorising medicinal products.
I 4.2. Application for a marketing authorisation
Twenty-one Member States responded to the EMA’s 
information request (section 2). They reported that the new 
psychoactive substance α-PVP is not the subject of an 
application for a marketing authorisation (48). The EMA also 
reported that the new psychoactive substance α-PVP is not 
the subject of an application for a marketing authorisation 
through the centralised procedure.
I 4.3. Suspended marketing authorisation
Twenty-one Member States responded to the EMA’s 
information request (section 2). They reported that there had 
been no cases of a suspended marketing authorisation that 
had been granted in respect of the new psychoactive 
substance α-PVP (48). The EMA also reported that the new 
psychoactive substance α-PVP is not the subject of a 
suspended marketing authorisation through the centralised 
procedure.
I 5. Conclusion
α-PVP is a synthetic cathinone derivative closely related to 
pyrovalerone and MDPV, both of which are synthetic 
stimulants that are controlled under the 1971 United Nations 
Convention on Psychotropic Substances. 
(48)  Austria, Belgium, the Czech Republic, Estonia, Finland, Iceland, Ireland, 
Poland, Spain, Sweden and the United Kingdom provided a response in 
relation to human and veterinary medicinal products. Croatia, Greece and 
Italy provided a response in relation to human medicinal products. France, 
Germany, Hungary, Latvia, the Netherlands, Portugal and Slovenia provided a 
response in relation to veterinary medicinal products.
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Data suggest that α-PVP is likely to be a potent 
psychostimulant with abuse liability and dependence 
potential in humans; these effects may be similar to MDPV.
α-PVP has been available in the European Union since at least 
February 2011 and has been detected in 28 Member States, 
Turkey and Norway. In most cases it has been seized as a 
powder, but other forms including tablets have been detected. 
Multi-kilogram quantities of α-PVP have been seized at 
European borders, which usually originate from China. This 
includes the seizure of more than 280 kg in 2015. Illicit 
production and tableting sites within the EU have also been 
seized. α-PVP is sold as a ‘research chemical’ online and is 
available in wholesale and consumer amounts.
One hundred and forty serious adverse events associated 
with α-PVP have been reported by nine Member States. This 
includes acute intoxications requiring hospitalisation and 
more than 100 deaths; in at least 23 of these deaths α-PVP 
was the cause of death or contributed to the death. Of 
concern is that α-PVP is being used by high-risk drug users, 
including those who inject.
We conclude that the health and social risks caused by the 
manufacture, trafficking and use of α-PVP, and the 
involvement of organised crime and possible consequences of 
control measures, could be thoroughly assessed through a 
risk assessment procedure in accordance with Article 6 of 
Council Decision 2005/387/JHA.
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FIGURE A1
Tableting site dismantled by the Hungarian police in Érd in 2013. Tablets containing pentedrone and 800 g of α-PVP were seized
I  Annex Pictures of dismantled tableting and production facilities of α-PVP and of seizures containing α-PVP. Provided by Europol
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FIGURE A2
Tableting site dismantled by the Hungarian police in 2014. Tablets containing pentedrone and 1.5 kg of α-PVP in powder form 
were seized in the storage location linked to this tableting site
FIGURE A3
Production facility seized in Chorzow, Poland in 2013
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FIGURE A4
Tablets containing α-PVP and other new psychoactive substances seized by Czech authorities. Sold as MDMA
FIGURE A5
Package containing 109 g of α-PVP seized in Slovakia
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